EAACI Congress 2024

31 May - 03 June 2024 Valencia, Spain

OAS 25 - Cuting edge mastocytosis: genetics, burden, and therapeutic

Sunday 02 Jun, 16:45 PM - 18:15 PM Valencia, Spain
Bilbao Oral Abstract Sessions
Abstract Text
16:45 000405
The Burden of Indolent Systemic Mastocytosis in Europe: Results From the PRISM Patient Survey
Abstract Text
16:57 001696
A new tryptase gene haplotype in human associates alpha-triplication and beta-deletion
Abstract Text
17:09 000307
Idiopathic mast cell activation syndrome infrequent among patients with suspected mast cell disorders
Abstract Text
17:21 000554
Prevalence of drug-induced anaphylaxis low among 470 patients with mastocytosis - A two-center retrospective study
Abstract Text
17:33 001032
Briquilimab, an Anti-Human CD117 Antibody, Effectively Treats Epicutaneous Allergen-Induced Atopic Dermatitis in Mouse Model Expressing Chimeric Human/Mouse CD117
Abstract Text
17:45 000223
Safety of Avapritinib in Indolent Systemic Mastocytosis (ISM): Longer Term Follow-up From the PIONEER Study